Treatment of early-stage HER2+ breast cancer-an evolving field

被引：8
|
作者：
Ferreira, Arlindo R. [1 ,2 ,3 ]
Saini, Kamal S. [4 ]
Metzger-Filho, Otto [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Univ Lisbon, Hosp Santa Maria, P-1649035 Lisbon, Portugal
[3] Univ Lisbon, Inst Med Mol, P-1649035 Lisbon, Portugal
[4] Univ Libre Bruxelles, Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
ECANCERMEDICALSCIENCE | 2015年 / 9卷
关键词：
breast neoplasm; trastuzumab; neoadjuvant therapy; adjuvant therapy; antibodies; monoclonal; humanised;
D O I：
10.3332/ecancer.2015.523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.
引用
收藏
页数：15
相关论文
共 50 条
  • [31] Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
    Fiúza M.
    Advances in Therapy, 2009, 26 (Suppl 1) : S9 - S17
  • [32] New directions in the neoadjuvant treatment of HER2+ breast cancer
    Hobbs, Evthokia A.
    Hurvitz, Sara A.
    BREAST CANCER MANAGEMENT, 2015, 4 (04) : 223 - 234
  • [33] Treatment of brain metastases in patients with HER2+ breast cancer
    Bravo Marques J.M.
    Advances in Therapy, 2009, 26 (Suppl 1) : S18 - S26
  • [34] ASO Author Reflections: Beyond the Binary: Using IHC Status to Predict Response to Neoadjuvant Therapy in HER2+ Early-Stage Breast Cancer
    Leah K. Winer
    Austin D. Williams
    Annals of Surgical Oncology, 2025, 32 (2) : 967 - 968
  • [35] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Untch, Michael
    Martin, Miguel
    de Laurentiis, Michelino
    Gligorov, Joseph
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 297 - 309
  • [36] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer Reply
    O'Sullivan, Ciara C.
    Holmes, Eileen
    Campbell, Christine
    Bradbury, Ian
    Zujewski, Jo Anne
    Gelber, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 640 - +
  • [37] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Michael Untch
    Miguel Martin
    Michelino De Laurentiis
    Joseph Gligorov
    Oncology and Therapy, 2021, 9 : 297 - 309
  • [38] HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
    Brown-Glaberman, Ursa
    Dayao, Zoneddy
    Royce, Melanie
    ONCOLOGY-NEW YORK, 2014, 28 (04): : 281 - 289
  • [39] Treatment of mild asymptomatic cardiotoxicity in early-stage HER 2-positive breast cancer. Is it justified?
    Oristrell, Gerard
    Burcet, Gemma
    Valente, Filipa
    Escriva-De-Romani, Santiago
    Arumi, Miriam
    Ferreira-Gonzalez, Ignacio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2023, 76 (06): : 480 - 483
  • [40] Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer
    Jerez, Yolanda
    Herrero, Blanca
    Arregui, Marta
    Moron, Blanca
    Martin, Miguel
    Echavarria, Isabel
    FUTURE ONCOLOGY, 2020, 16 (17) : 1165 - 1177
12345